Intermittent Androgen Deprivation in Patients With Stage D2 Prostate Cancer, Phase III.

Trial Profile

Intermittent Androgen Deprivation in Patients With Stage D2 Prostate Cancer, Phase III.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Bicalutamide (Primary) ; Goserelin (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Apr 2013 Status changed from active, no longer recruiting to completed.
    • 04 Apr 2013 Results published in the New England Journal of Medicine.
    • 06 Jun 2012 Planned end date changed from 1 Jun 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top